Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 7/20 | 0.46 |
| ▸ | BRAF | P15056 | 7/20 | 0.46 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | ABL1 | P00519 | 3/20 | 0.38 |
| ▸ | ABL2 | P42684 | 2/20 | 0.38 |
| ▸ | FLT3 | P36888 | 4/20 | 0.37 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.37 |
| ▸ | KIT | P10721 | 3/20 | 0.37 |
| ▸ | RAF1 | P04049 | 2/20 | 0.37 |
| ▸ | ARAF | P10398 | 2/20 | 0.37 |
| ▸ | EGFR | P00533 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20576240 | 1.00 | KDR (0.46) | KDRBRAFFGFR1ABL1ABL2 | |
| SCHEMBL20576549 | 0.93 | KDR (0.45) | KDRBRAFFGFR1ABL1ABL2 | |
| SCHEMBL20576546 | 0.93 | KDR (0.45) | KDRBRAFFGFR1ABL1ABL2 | |
| SCHEMBL21298661 | 0.91 | KDR (0.43) | KDRBRAFFGFR1ABL1ABL2 | |
| SCHEMBL20576577 | 0.90 | RORC (0.37) | KDRBRAFFLT3CHEK1KIT | |
| SCHEMBL21298643 | 0.90 | RORC (0.37) | KDRBRAFFLT3CHEK1KIT | |
| SCHEMBL20576579 | 0.90 | RORC (0.37) | KDRBRAFFLT3CHEK1KIT | |
| SCHEMBL21298632 | 0.89 | KDR (0.49) | KDRBRAFFGFR1ABL1ABL2 | |
| SCHEMBL20575949 | 0.88 | FLT3 (0.36) | KDRBRAFABL1ABL2FLT3 | |
| SCHEMBL20575947 | 0.88 | FLT3 (0.36) | KDRBRAFABL1ABL2FLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10392367-B2 | IRE1 small molecule inhibitors | QUENTIS THERAPEUTICS, INC. (US) | 2019-08-27 | — | — | US | disclosed |
| US-20180346447-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2018-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10392367-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | KDR 3965/4885BRAF 1396/4885FGFR1 3519/4885 |
| US-20180346447-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | KDR 3965/4885BRAF 1396/4885FGFR1 3519/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.